RNAZ · Insider Trading
TransCode Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by RNAZ officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-11 | Thomas A Fitzgerald | Chief Financial Officer | A | +185,000 deriv. | — |
| 2026-08-05 | CK Life Sciences Intl (Holdings) Inc | 10%+ Owner | C | +27,668,882 | — |
| 2024-06-18 | Magda Marquet | Director | A | +70,000 deriv. | — |
| 2024-06-18 | Philippe Calais | Director | A | +70,000 deriv. | — |
| 2024-06-18 | Thomas A Fitzgerald | Interim CEO, CFO | A | +650,000 deriv. | — |
| 2024-06-18 | Erik Manting | Director | A | +70,000 deriv. | — |
| 2023-10-02 | Thomas A Fitzgerald | Chief Financial Officer | Buy | +49,350 | +$25.17K |
| 2023-10-02 | Robert Michael Dudley | Chief Executive Officer | Buy | +98,000 | +$49.98K |
| 2023-06-22 | Robert Michael Dudley | Chief Executive Officer | Buy | +18,607 | +$48.66K |
| 2023-06-14 | Robert Michael Dudley | Chief Executive Officer | Buy | +19,000 | +$52.44K |
| 2023-06-13 | Robert Michael Dudley | Chief Executive Officer | Buy | +19,000 | +$52.44K |
| 2023-05-19 | Erik Manting | Director | A | +45,000 deriv. | — |
| 2023-05-19 | Thomas A Fitzgerald | Chief Financial Officer | A | +300,000 deriv. | — |
| 2023-05-19 | Robert Michael Dudley | Chief Executive Officer | A | +735,000 deriv. | — |
| 2023-05-19 | Magda Marquet | Director | A | +45,000 deriv. | — |
| 2023-05-19 | Philippe Calais | Director | A | +45,000 deriv. | — |
| 2023-05-10 | Philippe Calais | Director | A | +9,500 deriv. | — |
| 2023-05-10 | Magda Marquet | Director | A | +9,500 deriv. | — |
| 2023-05-10 | Erik Manting | Director | A | +9,500 deriv. | — |
| 2022-12-14 | Zdravka Medarova | Chief Technology Officer | A | +60,000 deriv. | — |
| 2022-12-14 | Thomas A Fitzgerald | Chief Financial Officer | A | +100,000 deriv. | — |
| 2022-12-14 | Zdravka Medarova | Chief Technology Officer | A | +33,000 deriv. | — |
| 2022-12-14 | Robert Michael Dudley | Chief Executive Officer | A | +135,000 deriv. | — |
| 2022-09-16 | Robert Michael Dudley | Chief Executive Officer | Buy | +20,000 | +$23.00K |
| 2022-06-22 | Erik Manting | Director | A | +9,500 deriv. | — |
| 2022-06-22 | Philippe Calais | Director | A | +9,500 deriv. | — |
| 2022-06-22 | Magda Marquet | Director | A | +9,500 deriv. | — |
| 2022-06-17 | Thomas A Fitzgerald | Chief Financial Officer | Buy | +12,000 | +$15.24K |
| 2022-06-01 | Robert Michael Dudley | Chief Executive Officer | Buy | +30,000 | +$55.38K |
| 2022-03-02 | Thomas A Fitzgerald | Chief Financial Officer | A | +52,000 deriv. | — |
| 2022-02-03 | Robert Michael Dudley | Chief Executive Officer | A | +135,000 deriv. | — |
| 2022-02-03 | Thomas A Fitzgerald | Chief Financial Officer | A | +33,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| CK Life Sciences Intl (Holdings) Inc | 10%+ Owner | 12,113,899 | $20.66M |
| Thomas A Fitzgerald | Chief Financial Officer | 2 | $3 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RNAZ quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.